| 1. |
Liu MB, He XY, Yang XH, et al. Interpretation of report on cardiovascular health and diseases in China 2023. Chin J Cardiovasc Med, 2024, 29(4): 305-324.
|
| 2. |
Sabik JF, Bakaeen FG, Ruel M, et al. The American Association for Thoracic Surgery and The Society of Thoracic Surgeons reasoning for not endorsing the 2021 ACC/AHA/SCAI coronary revascularization guidelines. J Thorac Cardiovasc Surg, 2022, 163(4): 1362-1365.
|
| 3. |
郝星, 黑飛龍, 侯曉彤. 2020年中國心外科手術和體外循環數據白皮書. 中國體外循環雜志, 2021, 19(5): 257-260.Chinese Society of Extracorporeal Circulation. White book of Chinese cardiovascular surgery and extracorporeal circulation in 2020. Chin J ECC, 2021, 19(5): 257-260.
|
| 4. |
Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J, 2017, 38(32): 2459-2472.
|
| 5. |
國家疾病預防控制局. 中國居民營養與慢性病狀況報告(2020). 北京: 人民衛生出版社, 2015.National Disease Control and Prevention Administration. Report on the nutrition and chronic disease status of Chinese residents (2020). Beijing: People's Medical Publishing House, 2015.
|
| 6. |
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J, 2020, 41(1): 111-188.
|
| 7. |
中國血脂管理指南修訂聯合專家委員會. 中國血脂管理指南(2023年). 中華心血管病雜志, 2023, 51(3): 221-255.Joint Committee on the Chinese Guidelines for Lipid Management. Chinese guidelines for lipid management (2023). Chin J Cardiol, 2023, 51(3): 221-255.
|
| 8. |
中國冠狀動脈旁路移植術后二級預防專家共識組, 中國醫師協會心血管醫師分會冠心病外科學組, 中華醫學會胸心血管外科學分會冠心病外科學組. 冠狀動脈旁路移植術后二級預防中國專家共識(2020). 中華胸心血管外科雜志, 2021, 37(4): 193-201.Working Group of the Chinese Expert Consensus on Secondary Prevention after Coronary Artery Bypass Surgery, The Task Force for Coronary Artery Disease of Chinese Association of Cardiovascular Surgeons (CACS), The Task Force for Coronary Artery Disease of Chinese Society of Thoracic and Cardiovascular Surgery (CSTCVS). Chinese expert consensus on secondary prevention after coronary artery bypass surgery (2020). Chin J Thorac Cardiovasc Surg, 2021, 37(4): 193-201.
|
| 9. |
Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet, 2010, 376(9753): 1670-1681.
|
| 10. |
Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med, 2017, 376(18): 1713-1722.
|
| 11. |
Antonopoulos AS, Odutayo A, et al. Development of a risk score for early saphenous vein graft failure: an individual patient data meta-analysis. J Thorac Cardiovasc Surg, 2020, 160(1): 116-127. e4.
|
| 12. |
de Vries MR, Simons KH, Jukema JW, et al. Vein graft failure: from pathophysiology to clinical outcomes. Nat Rev Cardiol, 2016, 13(8): 451-470.
|
| 13. |
Ezhov MV, Afanasieva OI, Il'ina LN, et al. Association of lipoprotein(a) level with short- and long-term outcomes after CABG: the role of lipoprotein apheresis. Atheroscler Suppl, 2017, 30: 187-192.
|
| 14. |
Zuo HJ, Nan N, Yang HX, et al. Impact of conventional cardiovascular risk factors on left internal mammary artery graft disease. Front Cardiovasc Med, 2022, 8: 705765.
|
| 15. |
Ding RJ, Ma CS, Chen H, et al. Control rate of increased low-density lipoprotein cholesterol levels in cardiology outpatients with coronary heart disease in Beijing. Chin J Cardiol, 2013, 41(3): 251-255.
|
| 16. |
Guo LW, Zhang Y, Wu YH, et al. Lipid compliance rate and influencing factors of ultra-high-risk patients with atherosclerotic cardiovascular diseases. Chinese Remedies Clin, 2024, 24(7): 443-447.
|
| 17. |
Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet, 2011, 378(9798): 1231-1243.
|
| 18. |
中華人民共和國國家衛生健康委員會醫政司. 肥胖癥中國診療指南(2024年版). 協和醫學雜志, 2025, 16(1): 90-108.Department of Medical Administration, National Health Commission of the People's Republic of China. Chinese guidelines for the clinical management of obesity (2024 Edition). Med J Peking Union Med Coll Hosp, 2025, 16(1): 90-108.
|
| 19. |
Bi L, Yi J, Wu C, et al. Atherosclerotic cardiovascular disease risk and lipid-lowering therapy requirement in China. Front Cardiovasc Med, 2022, 9: 839571.
|
| 20. |
Liu C, Liu Q, Xiao X. Effectiveness and safety of combinational therapy compared with intensified statin monotherapy in patients with coronary heart disease. Exp Ther Med, 2018, 15(6): 4683-4688.
|
| 21. |
Altowaijri A, Phillips CJ, Fitzsimmons D. A systematic review of the clinical and economic effectiveness of clinical pharmacist intervention in secondary prevention of cardiovascular disease. J Manag Care Pharm, 2013, 19(5): 408-416.
|